- Positions Intellia for R&D growth and progress toward clinical studies - - Accommodates hiring plans to support pipeline of CRISPR/Cas9 based therapeutics -
CAMBRIDGE, Mass., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA ), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced the move to its new laboratory facilities at 40 Erie Street, in Cambridge. In recognition of Intellia’s leadership in genome editing, Intellia CEO and Founder Nessan Bermingham, Ph.D., President and CEO of the Massachusetts Life Sciences Center Travis McCready, and President and CEO of MassBio Bob Coughlin, will inaugurate the new facility today at an evening ribbon cutting ceremony.
“The field of genome editing is rapidly evolving and our work to develop therapies for patients requires that we have the infrastructure necessary for R&D growth and prepare for preclinical studies and clinical trials,” said Nessan Bermingham, Ph.D., Chief Executive Officer and Founder, Intellia Therapeutics. “To reach our goals, we continue to recruit top talent and ensure our quality workforce has the appropriate facilities and tools necessary to translate CRISPR/Cas9 into life-transforming products.”
“This new facility allows Intellia to further advance our scientific programs and to continue to leverage our Massachusetts location alongside leading biotech research and academic institutions,” Dr. Bermingham added.
About Intellia’s New Headquarters The new Intellia headquarters was specifically designed to accommodate the Company’s growing R&D, operations teams and administrative staff . Additionally, Intellia will maintain operations at its current facility at 130 Brookline Street in Cambridge. The new facility will increase Intellia’s total laboratory and office space from the current 15,000 sq. ft. to more than 80,000 sq. ft. and will allow the company to double its team to more than 200 employees.
“Intellia Therapeutics’ new headquarters is a testament to the potential of the company and the promise their transformative gene therapy represents to patients and their families living with severe and life-threatening diseases,” said Governor Charlie Baker. “The innovations coming out of Massachusetts have a dramatic impact across the global life sciences sector, and we look forward to Intellia Therapeutics’ continued growth and contributions to this field.”
“We are thrilled to celebrate Intellia Therapeutics’ growth as a great example of the opportunity available to companies in the Massachusetts life sciences ecosystem,” said Travis McCready, President & CEO of the Massachusetts Life Sciences Center. “The genomics space is exciting, carrying enormous potential for saving lives and improving patient care. Companies like Intellia have provided a strong blueprint for success to other genomics startups in Massachusetts.”
“We are excited to celebrate with Intellia Therapeutics as they take this significant step to expand into new headquarters,” said Robert K. Coughlin, President & CEO of MassBio. “We are proud to have Intellia as part of the Massachusetts life sciences community and look forward to their successes as they advance the use of cutting-edge genome editing to develop treatments and cures for patients around the world.”
About Intellia Therapeutics Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com ; Follow us on Twitter @intelliatweets.
Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia Therapeutics undertakes no duty to update this information unless required by law.
Intellia Contacts:
| Media: Jennifer Mound Smoter Chief External Affairs & Communications Officer +1 857-706-1071 jenn.smoter@intelliatx.com | Investors: John Graziano Trout Group + 1 646-378-2942 jgraziano@troutgroup.com Chad Rubin Trout Group + 1 646-378-2947 crubin@troutgroup.com |
